

CLINICAL CASE OF TREATMENT OF UROGENITAL CHLAMYDIOSIS

Islamov Nurali Hikmatovich

*assistant at the department of skin and venereal diseases,
Samarkand state medical university*

Ermanov Rustam Temirovich

*assistant at the department of epidemiology
Samarkand state medical university*

Annotation: this article attempts to reveal the main reasons for the optimization of immunocorrection schemes in the treatment of urogenital chlamydia using an integral assessment of the state of various microbiocenoses of the human body. To carry out scientific work, the author studied the microflora of the mucous membranes of the vagina, cervical canal, urethra, prostate gland, urine samples, contents of the large intestine and peripheral blood in 193 patients (124 women and 69 men) with chronic chlamydial infection. The problem in question is still little studied, therefore, requires more thorough research.

Key words: Chlamydia, sexually transmitted infection.

Introduction: Chlamydia is a sexually transmitted infection caused by *Chlamydia trachomatis*. It is one of the most common sexually transmitted diseases.

According to statistics, 100 million people fall ill with chlamydia every year in the world, and the number of people infected with chlamydia around the globe, according to the most conservative estimates, reaches one billion. According to WHO and numerous domestic and foreign researchers, urogenital chlamydia is one of the most common sexually transmitted diseases, therefore, for modern venereology, the creation of the most effective means of treating so-called non-gonococcal inflammatory diseases of the genitourinary system remains relevant.

According to various sources, from 5 to 15% of young sexually active people are infected with chlamydial infection. In patients of dermatovenerological dispensaries of the Russian Federation, this infection occurs 2-3 times more often than gonorrhoea. The frequency of non-gonococcal inflammatory diseases of the genitourinary system is 5-6 times higher than that of gonorrhoea, their incubation period is longer, clinical manifestations are less pronounced, complications occur more often, chlamydia predominates among pathogens. The widespread occurrence of chlamydial infection is associated primarily with the asymptomatic

course of the disease.

Aim: optimization of immunocorrection schemes in the treatment of urogenital chlamydia using an integral assessment of the state of various microbiocenoses of the human body.

Materials and methods: we studied the microflora of the mucous membranes of the vagina, cervical canal, urethra, prostate gland, urine samples, contents of the large intestine and peripheral blood in 193 patients (124 women and 69 men) with chronic chlamydial infection. Monitoring was carried out against the background of complex etiopathogenetic treatment with the use of combined immunocorrection with roncoleukin, betaleykin, pyrogenal, and interalem-P. The control group consisted of 46 clinically healthy patients (23 women and 23 men) with no laboratory and instrumental signs of infectious and inflammatory diseases.

Results: an integral assessment of combined immunocorrection by using a neural network established a high efficiency in changing microbiocenoses in women when using the full course - phased immunocorrection (52.2–100%): combined use of ronco-leukin and pyrogenal (40–60%); negative efficiency when using Roncoleukin (-4.8; -14.6%); interal-P and betaleykin (-50%). In men, the highest efficiency of changing microbiocenoses was stated when using the full course (47.1–100%); roncoleukin (50–100%); roncoleukin and betaleykin (42.9-100%); negative efficiency in the combined use of betaleykin and pyrogenal (-25.3%).

Conclusions:

1. The method of mathematical modeling of various microbiocenoses of the body allows us to evaluate the effectiveness of the use of immunocorrection schemes in the treatment of urogenital chlamydia.

2. Complex step-by-step immunocorrection has the highest efficiency in the treatment of urogenital chlamydia.

3. The method of mathematical modeling proved the greatest efficiency of the full course for microbiocenosis of the cervical canal and blood in women and microbiocenosis of urine in men. At the same time, the negative effectiveness of individual immunocorrection schemes is noted.

Literature:

1. Абдуллаев Х., Толибов М. Allergodermatozlar bilan bog'liq bo'lgan vulgar acneni kompleks davolash Samaraligini o'rganish //Журнал гепато-гастроэнтерологических исследований. – 2021. – Т. 2. – №. 3.2. – С. 73-74.
2. Пуяевна П. У. et al. DERMATOSCOPIC PAINTING SOME COMMON DERMATOSES //World scientific research journal. – 2023. – Т. 16. – №. 2. – С. 107-120.
3. Пуяевна П. У. et al. MODERN TRENDS IN TREATMENT SICK MICROSPORIA //World scientific research journal. – 2023. – Т. 16. – №. 2. – С. 98-106.

4. Kholikovich E. S. et al. APPLICATION OF" BETASALIK" OINTMENT IN THE THERAPY OF CHRONIC INFLAMMATORY AND ALLERGIC DERMATOSES //Journal of new century innovations. – 2023. – T. 31. – №. 3. – C. 56-62.
5. Jo‘raqulovich U. A. et al. ADVANTAN FOYDALANISH ALLERGIY VA YALIGLI DERMATOZLARNI TASHQI TERAPIYA //World scientific research journal. – 2023. – T. 16. – №. 2. – C. 56-66.
6. Abdusalamovich R. I. et al. AZELAY KISLOTA PAYLASHMALARI-PAPULOZ-PUSTULOZ VA ROSE AKNELARINI DAVOLASH //World scientific research journal. – 2023. – T. 16. – №. 2. – C. 73-79.
7. Abdullaev X., Tolibov M. Allergodermatozlar bilan bog‘liq bo‘lgan vulgar akneni kompleks davolash Samaraligini o‘rganish //Jurnal gepato-gastroenterologik issledovaniy. – 2021. – T. 2. – №. 3.2. – C. 73-74.
8. Tolibov M. M. et al. SEVORAN USAGE IN THE MANAGEMENT OF PAPULOSQUAMOUS DERMATOSES //RESEARCH AND EDUCATION. – 2023. – T. 2. – №. 6. – C. 112-119.
9. Tillaqobilov I. B., Abdullaev X. D., qizi Subxonova Z. S. PSORIAZNI DAVOLASHDA MONOKLONAL ANTIJALARNING SAMARALILIGINI BAHOLANISH //Educational Research in Universal Sciences. – 2024. – T. 3. – №. 1. – C. 310-313.
10. Tillaqobilov I. B., Abdullaev X. D., qizi Subxonova Z. S. EKSIMER LAZERINING (EXILITE MU) DERMATOLOGIYADA KLINIK QO‘LLANILISHI //Educational Research in Universal Sciences. – 2024. – T. 3. – №. 1. – C. 295-299.
11. Utayev A. J., ugli Toshev S. U., Abdullaev X. D. EVALUATING THE EFFICACY OF DERMOSCOPIC METHOD IN DISTINGUISHING BETWEEN MYCOSIS AND ALOPECIA IN PEDIATRIC PATIENTS //Modern Scientific Research International Scientific Journal. – 2024. – T. 2. – №. 1. – C. 133-138.
12. Utayev A. J., ugli Toshev S. U., Abdullaev X. D. EVALUATION OF THE EFFECTIVENESS OF FACIAL ATOPIC DERMATITIS TREATMENT METHODS //Modern Scientific Research International Scientific Journal. – 2024. – T. 2. – №. 1. – C. 139-144.
13. Toshev S. U. et al. MOLECULAR SIGNIFIERS IN SYPHILITIC INFECTION AND THEIR ROLE IN MORBIDITY RATES //RESEARCH AND EDUCATION. – 2023. – T. 2. – №. 6. – C. 101-111.
14. Ахмедова М. М., Абдуллаев Д. М., Тошев С. У. ИСПОЛЬЗОВАНИЯ МАЗЬИКУРАЛИМУС ПРИ ЛЕЧЕНИИ КРАСНОГО ПЛОСКОГО ЛИШАЯ //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – T. 2. – №. 3. – C. 191-193.
15. Тошев С. У., Аширов З. Ф., Абдуллаев Х. Д. ЛЕЧЕНИЕ ВИТИЛИГО 308-НМ ЭКСИМЕРНЫМ ЛАЗЕРОМ //Актуальные аспекты медицинской деятельности. – 2021. – C. 240-243.
16. Hikmatovich I. N., Xolmatovich J. A., Axtamovna A. F. Applications of Elidel for Lichen Plane //Texas Journal of Medical Science. – 2022. – T. 8. – C. 113-115.
17. Islamov N. H., Jalilov A. X., Achilova F. A. IJTIMOIIY-GIGIENIK TURSHIY SHARTLARNING O‘QUVCHILAR SALOMATLIGIGA TA‘SIRI //Educational Research in Universal Sciences. – 2023. – T. 2. – №. 14. – C. 314-318.
18. Islamov N. H. et al. PRINCIPLES OF TREATMENT OF LARYNGOTRACHEITIS IN CHILDREN //Modern Scientific Research International Scientific Journal. – 2023. – T. 1. – №. 7. – C. 136-142.
19. Islamov N. H., Jalilov A. X., Achilova F. A. DEVELOPMENT OF PAPILLOMAVIRUS INFECTION IN MEN //Modern Scientific Research International Scientific Journal. – 2023. – T. 1. – №. 7. – C. 128-135.
20. Hikmatovich I. N., Temirovich E. R., Muradovich Y. M. O‘SMIRLARDA YUZAKI PYODERMANI DAVOLASHDA TOPIKAL TERAPIYA //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – C. 355-358.